Purpose: Skin metastases of breast cancer remain a therapeutic challenge. Toll-like receptor 7 agonist imiquimod is an immune response modifier and can induce immunemediated rejection of primary skin malignancies when topically applied. Here we tested the hypothesis that topical imiquimod stimulates local anti-tumor immunity and induces the regression of breast cancer skin metastases.
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INTRODUCTION
Skin metastases of solid tumors remain a therapeutic challenge. Breast cancer is the second most common tumor, after melanoma, to metastasize to the skin [1, 2] . Breast cancer skin recurrence most frequently manifest after mastectomy and can present as firm nodules, diffuse infiltration or ulcerative lesions, often in proximity of the mastectomy scar. Initial management of recurrences usually includes resection and radiation, but skin metastases tend to recur and herald diffuse metastatic spread.
Furthermore, cutaneous metastases affect quality of life and become a debilitating experience for the patient as progression of disease leads to chest wall ulceration, bleeding and super-infection. Therefore, novel treatment approaches are warranted.
Imiquimod is a synthetic imidazoquinoline and Toll-like receptor (TLR)-7 agonist [3] .
TLRs are highly conserved pattern recognition receptors that alert the host to invading pathogens, thereby activating an innate immune response directly and an adaptive immune response, secondarily. TLR7 is located on endosomal membranes of antigenpresenting cells, including myeloid (mDCs) and plasmacytoid dendritic cells (pDCs), monocytes, and macrophages. TLR7 activation induces secretion of proinflammatory cytokines, predominantly interferon (IFN)-α, interleukin (IL)-12, and tumor necrosis factor-α, and enhances DC maturation and antigen presentation [4] . This immunostimmulatory ability can be harnessed to promote anti-tumor immunity, either by applying the TLR agonist locally onto cancers or administering it as an adjuvant for cancer vaccines. Therefore TLR agonists are included in the ranked National Cancer Page | 5 [5, 6] . Imiquimod is approved by the Food and Drug Administration (FDA) in a topical 5% formulation for the treatment of external genital warts, superficial basal cell carcinoma, and actinic keratosis. Topically applied, imiquimod exerts profound immunomodulatory effects on the tumor microenvironment leading to immune-mediated clearance of primary skin and mucosal malignancies [7, 8] .
Based on imiquimod's efficacy in primary skin tumors and encouraged by anecdoctal reports of anti-tumor efficacy in skin metastases of melanoma and breast cancer [9 , 10], we tested the hypothesis that treatment with topical imiquimod could induce the regression of breast cancer skin metastases. In a prospective phase II trial topical imiquimod 5% was applied to all cutaneous metastases and local anti-tumor activity and toxicity were measured after an 8-week treatment course. Tumor punch-biopsies were obtained before and after imiquimod treatment from each patient to study the immunological changes in the tumor microenvironment.
METHODS

Patient eligibility
Women >18 years of age with biopsy-proven breast cancer and measurable skin metastases (chest wall recurrence or skin metastases) not suitable for definitive surgical resection and/or radiotherapy, Eastern Cooperative Oncology Group performance status of 0 to 1, adequate bone marrow and organ function were eligible. Concurrent systemic cancer therapy (hormones, biologics or chemotherapy) was allowed to continue only if, on a stable regimen for ≥12 weeks, skin metastases did not respond. The trial required completion of prior radiotherapy and hyperthermia to the target area >4 weeks and >10 weeks respectively, prior to study entry. Systemic disease assessment by CT/PET-CT imaging pre-and post-treatment was not required by protocol and was left to the discretion of the treating physician. All patients provided a written informed consent for participation in this IRB-approved study (clinicaltrials.gov identifier NCT00899574).
Trial design
The primary objective of this trial was to determine the local anti-tumor effect of topical TLR7 agonist imiquimod 5% cream in breast cancer patients with skin metastases.
Secondary objectives were to assess toxicity and to study the immunological effects in the tumor microenvironment induced by imiquimod treatment. The trial was designed as an open label, single arm study to test the null hypothesis that the local anti-tumor effect (CCR and PR) was P<0.05 versus the alternative that P>0.20. An optimal two-stage Simon design was used, in which 10 patients were to be enrolled in stage one, with an expansion to stage 2 with an additional 19 patients if there was at least one responder in stage 1. The overall alpha level for this design was 0.047 with power of 0.801. At study entry, patient demographic and tumor characteristics (pathology, grade of differentiation, hormone receptor and human epidermal growth factor receptor (Her)-2 status), metastatic sites and treatment history were collected.
Treatment
Imiquimod 5% cream (Aldara , up to a maximum of 6 packets per day. These dose determinations were based on extrapolation from clinical experience with dosing of up to 6 packets per application in patients with actinic keratoses [11, 12] . Imiquimod application was recorded by means of patient diaries and compliance was encouraged and monitored by weekly phone calls of study personnel to patients.
Response evaluation
Tumor assessment was performed by physical examination at baseline and after the 8-week treatment course; visible and/or palpable cutaneous metastases were outlined on transparent film and uploaded into the Image J computer program (version 1.42q, provided by the National Institutes of Health, USA) for digital calculation of the affected surface area (ROI, region of interest). Computer-aided image analysis of the ROI was compared before and after treatment to assess response. As chest wall/skin lesions can be multifocal, confluent and highly irregular, response criteria for this study were chosen based on criteria established for chest wall tumors by the European Organisation for Research and Treatment of Cancer (EORTC) modified from assessment of Kaposi's sarcoma skin lesions [13] . These response criteria are defined as follows: complete clinical response (CCR, absence of any detectable residual disease), partial response 
Tumor biopsies and immune analyses
Tumor biopsies (4mm diameter punch) were obtained at baseline and after imiquimod treatment (3-5 days after completing an 8 week treatment cycle) from each patient.
Each biopsy specimen was bisected; one half was processed into paraffin-embedded Breast cancer tissue from biopsies before and after imiquimod treatment was cultured in 1ml RPMI supplemented with 10% FBS, gentamicin and IL-2 (10ng/mL) in 24-well plates at 37°C in a 5% CO 2 incubator, IL-2 media was replenished every 2 to 3 days. 
Statistical analysis
Characteristics of patients are summarized using descriptive statistics including median and ranges for continuous variables and frequencies for categorical variables.
Response rates (CCR+PR) were estimated at the conclusion of the first stage of the trial along with exact 95% confidence intervals. Safety data was summarized by body system and type and most severe Common Terminology Criteria for Adverse Events 
RESULTS
Ten women enrolled and completed the first stage of this two stage study. The median age was 50 years. Demographic and tumor characteristics as well as treatment history are shown in Table 1 . Seven women presented with a chest wall recurrence, and 3 women presented with skin involvement of a large primary breast cancer in the setting of systemic metastases. All women had failed prior treatment for metastatic/recurrent disease, ranging from 1-3 lines of hormonal therapy (average 2) and 1-5 lines of chemotherapy (average 2.5). Based on the skin area involved, six patients applied 1 packet per day, whereas 4 applied more than 1 packet per day. A second treatment cycle was administered in 2 patients.
Patient compliance, defined as the number of administered applications divided by the number of prescribed applications during the entire study period, was excellent with 4 patients not missing any doses, and 6 patients having a compliance score of 95% or greater (1-2 missed doses).
Safety
The treatment was well tolerated, with transient mild to moderate local and systemic adverse events (AEs) consistent with the expected immunomodulatory effects of imiquimod. There were no serious, life-threatening or severe grade AEs and no patient required permanent treatment discontinuation due to AEs. Systemic AEs occurred in 4 of 10 patients (40%), with flu-like symptoms being the most frequent ( Table 2) . One patient who received 6 packets/day experienced fever, fatigue and depression on treatment, similar to symptoms observed with systemic interferon alpha treatment [14] .
The increase of intratumoral as well as circulating IFN-α2 concentrations (from 7 to 19 pg/ml in plasma) with imiquimod treatment in this patient suggests a systemic spillover effect of locally induced cytokines.
The most frequently observed AEs were local, at the application site, and were experienced by 7 of 10 patients ( Table 2) . Symptoms included itching, burning and pain at the target site while signs included erythema, desquamation and infection. Topical antibiotics were administered for superficial infection at the treatment site, as indicated.
Patient discomfort due to local or systemic AEs, regardless of grade, was successfully managed with temporary dosing interruptions (one patient for 3 weeks) and subsequent reduction of the application frequency from 5x to 3x per week (three patients).
Tumor response
Local tumor response after an 8 week cycle of imiquimod treatment was observed in 2 patients (20%; exact 95% CI 3% -56%), both of whom achieved a clinical PR at the chest wall ( Table 3) . Five patients maintained SD, 1 had a NR, and 2 had PD (development of new cutaneous lesions outside of the treatment field during the study).
The decision to close the single agent trial, even though the criterion for moving to the second stage was met with a response rate of 20% in stage one, was based on the fact that a new combination trial of imiquimod and local radiotherapy was designed, reflecting promising pre-clinical findings of a combination of imiquimod and local radiotherapy (companion manuscript submitted). The decision to conclude the trial after 
achieved response rate of 20% with its 95%CI was reassuring that imiquimod as single agent has efficacy. Interestingly, two of the 10 patients treated in the present study (both with local SD on study) experienced a complete clinical remission upon treatment with a subsequent systemic regimen (fulvestrant). In both women the complete remission in the skin lesion was associated with a systemic complete response (pulmonary and osseous in one patient, mediastinal lymph node and adrenal metastases in the second patient) and have been maintained for over one year (details are being reported separately).
Immune correlates
To monitor the immune response at the tumor site, we examined TILs in paraffinembedded tissue sections (Figure 1 ) and in vitro cultures as well as local cytokines in tumor supernatants (Figure 2) . Viable tumor punch biopsies were successfully obtained from all patients before and after treatment. The supernatant after 24 hour ex vivo culture was obtained from all samples, and TIL cultures were successfully grown from 7/20 punch biopsy specimens.
Histological evaluation revealed tumor involvement of skin for all patients before and after imiquimod treatment, with diffuse infiltration extending from the superficial dermis to the subcutis, and variable density of tumor cells occupying from 10 to 80% of the tissue examined. No significant differences were observed in vascularity or degree of apoptotic changes when pre-treatment biopsies were compared to post-treatment ones.
Intratumoral T cell infiltrates were present in all specimens at baseline, varying from a 
sparse infiltrate (<5 CD3+ cells per HPF) to strong infiltration (65 CD3+ cells per HPF).
While it was feasible to culture TILs from small tumor punch biopsy specimens, the rate of success in establishing ex vivo TIL cultures was related to lymphocyte density: 7 cultures were established from 14 tumors that had >12 CD3+ cells per HPF, while none could be grown from the 6 tumors with <12 CD3+ cells infiltrating the metastasis. TILs commonly displayed a CCR7-/CD45RO+ effector memory and CCR6+ phenotype compared to PBMC, as shown in an example ( Figure 3A) . 
DISCUSSION
This is the first report on the efficacy of topical imiquimod in breast cancer skin metastases in patients studied in a prospective trial. Despite the fact that the 10 women accrued were heavily pretreated and had refractory breast cancer skin metastases, the response rate was 20%, with a partial response was achieved in two patients.
Imiquimod 5% was applied 5x per week, the dosing frequency used for the treatment of superficial basal cell carcinoma (sBCC) and in a report of two breast cancer patients who experienced a CR at 6 months [9] . Our trial demonstrated feasibility and excellent [7, [15] [16] [17] [18] [19] [20] . Until now, data from cutaneous metastases treated in prospective studies with topical imiquimod alone were lacking. In the current study, pre-existing lymphocytic infiltrates within the cutaneous metastases were highly variable and ranged from sparse to diffuse. Biopsies after an 8 week treatment course of imiquimod showed lack of consistent quantitative changes of the infiltrate.
Furthermore, no increases in pDCs were seen post-treatment (not shown). These observations are in contrast to both our prior study showing that percutaneous stimulation of TLR7 via imiquimod in healthy skin (without immune cell infiltrates pretreatment) attracts pDCs and induces an inflammatory infiltrate mainly composed of T cells [21] , and to the results of a recent study of preoperative imiquimod treatment of primary malignant melanoma demonstrating an increase in T cell infiltrates [15] . Effects of imiquimod may depend on the pre-existing tumor microenvironment, although the timing of biopsy in our trial compared to the other two studies (after 8 weeks versus 1-2 weeks of imiquimod application) might also have contributed to the difference. Table 1) . This difference may have contributed to the disparate response, as we have previously observed differences between IDC and ILC in their interaction with the local immune system [22] . Overall, the variability of TILs infiltrate (Supplemental Figure 1) and local cytokine milieu among all patients after and even before treatment points to the complexity of the interactions between tumor and host immune system in the setting of skin metastases. Genetic features of the patient may contribute to the differential response. Single-nucleotide polymorphisms have been described for TLR7 including alleles that are associated with treatment outcomes for viral infections [23] . Likewise, a TLR4 loss-of-function allele has been shown to impact outcome of breast cancer patients post-treatment [24] , suggesting that genetic variation might account for the diverse response to TLR agonists.
Research. 
Limitations of this study are the small number of patients which precludes the identification of significant differences between responders and non-responders, the single arm design without a comparator group as well as the option for patients to continue on a systemic regimen concurrently (if no prior response in skin), which may have affected the immunological response.
As mentioned two patients who had SD on imiquimod and were subsequently switched to fulvestrant, an estrogen receptor antagonist, had a complete clinical response to that regimen. Since CRs were rarely seen in a phase III trial of fulvestrant (only 4 of 362 women) [25] , it is reasonable to hypothesize that immune effects of imiquimod may have contributed to their outcome. Unexpectedly higher response rates to chemotherapy have been reported in several solid tumors, when chemotherapy was preceded by cancer vaccination [26] [27] [28] [29] [30] . Recent evidence that anti-tumor immunity contributes to the response to chemotherapy [24] raise the possibility that immunotherapy may condition the host immune system to achieve an anti-tumor effect synergistic with at least some cytocidal treatments.
Activation of TLRs not only induces inflammatory cytokines but can also trigger negative regulatory circuits, for example by promoting the secretion of IL-10 [31, 32] , as recently demonstrated in the neu-transgenic mouse model of breast cancer in which IL-10 upregulation was shown to limit imiquimod's therapeutic effect [33] . In our series, local levels of IL-10, as measured in tumor supernatants, did not show a significant change 
with imiquimod treatment, although a decrease was seen in two patients including responder 2 (Figure 2A ). Circulating IL-10 was detectable in 4 of 10 patients, but there was no trend to increase with imiquimod treatment ( Figure 2B ). In summary, we have shown that topical imiquimod can be a useful treatment modality for breast cancer metastatic to skin or chest wall. Importantly, data indicate that imiquimod is able to promote a pro-immunogenic tumor microenvironment in metastatic breast cancer. To improve the efficacy of topical imiquimod, we have studied a combinatorial approach with local radiotherapy in the TSA murine model of breast cancer with cutaneous involvement. Radiotherapy is a frequently used treatment modality for chest wall recurrences and has been shown to synergize with immunotherapies [34, 35] . In this preclinical model, the combination with topical 
